CyTOF profiling of bone marrow immune dynamics across myeloma stages [0.03%]
用于多发性骨髓瘤各阶段骨髓免疫细胞动态分析的CyTOF技术
Dana Cholujova,Gabor Beke,Lubos Klucar et al.
Dana Cholujova et al.
Multiple myeloma (MM) orchestrates a profound disruption of immune balance within the bone marrow (BM) microenvironment, driving disease progression and therapeutic resistance. To better understand these complex immune dynamics, we used hig...
Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors [0.03%]
低甘油三酯水平与接受免疫检查点抑制剂治疗患者的免疫相关不良事件风险增加有关
Nora Möhn,Emily Narten,Laura Duzzi et al.
Nora Möhn et al.
Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical rel...
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages [0.03%]
CXCR4拮抗剂与PD-1抑制剂II期临床试验用于转移性胰腺癌，募集T细胞的同时也招募了免疫抑制型巨噬细胞
Katherine M Bever,Sarah M Shin,Jennifer N Durham et al.
Katherine M Bever et al.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and myeloid-rich microenvironment that confer resistance to immunotherapies. Previous studies demonstrated that disrupting the immune-stroma CXCR4-CXCL12 axis facilita...
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma [0.03%]
淋巴耗竭、肿瘤浸润性淋巴细胞以及高剂量和低剂量IL-2后使用派姆单抗治疗转移性黑色素瘤患者的疗效
Merve Hasanov,Simin Kiany,Marie-Andrée Forget et al.
Merve Hasanov et al.
This study evaluated the efficacy and safety of unengineered tumor-infiltrating lymphocytes (TILs) combined with pembrolizumab and either high (HD, Arm-1) or low (LD, Arm-2) doses of IL-2 in patients with metastatic melanoma (MM). Patients ...
A laminin α4-CD8+ T cell axis shapes the prognostic impact of macrophages and regulatory T cells in early-stage colorectal cancer [0.03%]
lamininα4-CD8+T细胞轴可塑早期结直肠癌巨噬细胞和调节性T细胞的预后价值
Elena Nonnast,María Jesús Fernández-Aceñero,Tirso Pons et al.
Elena Nonnast et al.
The crossing of the endothelial basement membranes (BMs) is a limiting step for leukocyte diapedesis. Heterotrimeric laminins (LMs) containing α4- and α5-chains are major BM components with opposite effects on transendothelial migration. ...
A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy [0.03%]
局部癌症免疫治疗中识别具有疗效的转基因的临床前模型
Arne Menze,Dmitrij Ostroumov,Hans Heinrich Wedemeyer et al.
Arne Menze et al.
The efficacy of systemic immunotherapies is limited for poorly immunogenic tumors which suppress T cell priming and tumor infiltration. Modern antigen carriers including viral vectors and messenger RNA/lipid nanoparticle (LNP) combinations ...
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients [0.03%]
在真实世界证据生物标志物研究中，PD-1、LAG-3和TIM-3在尿路上皮癌浸润性CD8 T细胞中的表达与抗阿特朱单抗治疗反应的关系
Carlos E de Andrea,Marta Abengozar-Muela,José Ángel Arranz et al.
Carlos E de Andrea et al.
Blockade of the PD-1/PD-L1 pathway is part of the standard treatment for advanced urothelial cancer, but reliable predictive biomarkers have not been identified. Here, we analyze with Multiplexed Quantitative Immunofluorescence the pretreat...
Tumor-infiltrating B cells produce tumor-specific antibodies and may contribute to suppressing tumor in head and neck squamous cell carcinoma [0.03%]
头颈鳞状细胞癌肿瘤浸润B细胞产生肿瘤特异性抗体并可能有助于抑制肿瘤生长
Junsei Sameshima,Hu Chen,Naoki Kaneko et al.
Junsei Sameshima et al.
The involvement of T cells, particularly cytotoxic T cells, in tumor immunity has been reported, but the roles of B cells and antibodies in tumor immunity remain unclear. Previous studies have primarily focused on circulating B cells in the...
Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab [0.03%]
免疫相关的肝炎和垂体炎与接受伊匹单抗联合纳武单抗治疗的黑色素瘤患者的生存优势相关
Hifaa Al Remawi,Maria Lindén,Zhiyuan Zhao et al.
Hifaa Al Remawi et al.
Combination CTLA-4 (ipilimumab) and PD-1 (nivolumab) checkpoint inhibition (dual-ICI) improves survival in patients with advanced melanoma. However, many patients also experience immune-related adverse events (irAE) that require systemic tr...
Pan-cancer single cell transcriptomic clustering reveals heterogeneous CD8+ exhausted T cell populations with different immune checkpoint inhibitor responses [0.03%]
泛癌单细胞转录组聚类揭示了对免疫检查点抑制剂反应不同的异质性CD8⁺耗竭T细胞群
Rui Mu,Rasha Barakat,David H Gutmann
Rui Mu
In most cancers, T lymphocytes comprise an essential cellular component of the non-neoplastic microenvironment, where they have the capacity to both suppress and support tumor growth. One specialized T lymphocyte population is the CD8+ exha...